Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90B1 | P14625 | 2/20 | 0.81 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.79 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.79 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.79 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.79 |
| ▸ | TSHR | P16473 | 3/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.73 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.73 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.73 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.73 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3477644 | 1.00 | HSP90B1 (0.81) | HSP90B1ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL3422914 | 1.00 | HSP90B1 (0.81) | HSP90B1ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL926929 | 1.00 | HSP90B1 (0.81) | HSP90B1ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL3484693 | 1.00 | HSP90B1 (0.81) | HSP90B1ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL1949851 | 0.94 | HSP90B1 (0.72) | HSP90B1ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL12935991 | 0.89 | HSP90B1 (0.83) | HSP90B1ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL14140832 | 0.89 | HSP90B1 (0.83) | HSP90B1ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL15462103 | 0.89 | ADORA3 (0.77) | HSP90B1ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL19423461 | 0.89 | ADORA3 (0.77) | HSP90B1ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL13966964 | 0.88 | HSP90B1 (0.81) | HSP90B1ADORA2AADORA3ADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222228-B2 | Substituted aryl piperidinylalkynyladenosines as A2AR agonists | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2012-07-17 | — | — | US | disclosed |
| US-20110091385-A1 | SUBSTITUTED ARYL PIPERIDINYLALKYNYLADENOSINES AS A2AR AGONISTS | PGXHEALTH, LLC (US) | 2011-04-21 | — | — | US | disclosed |
| US-7888329-B2 | Substituted aryl piperidinylalkynyladenosines as A2AR agonists | PGXHEALTH, LLC (US) | 2011-02-15 | — | — | US | disclosed |
| US-7737127-B2 | 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2010-06-15 | — | — | US | disclosed |
| US-20090280059-A1 | SUBSTITUTED ARYL PIPERIDINYLALKYNYLADENOSINES AS A2AR AGONISTS | PGXHEALTH, LLC (US) | 2009-11-12 | — | — | US | disclosed |
| US-7589076-B2 | Substituted aryl piperidinylalkynyladenosines as A2AR agonists | PGX HEALTH, LLC (US) | 2009-09-15 | — | — | US | disclosed |
| US-20090170803-A1 | ADJUNCTIVE TREATMENT OF BIOLOGICAL DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-07-02 | — | — | US | disclosed |
| US-7396825-B2 | Agonists of A2A adenosine receptors for treatment of diabetic nephropathy | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2008-07-08 | — | — | US | disclosed |
| US-20070270373-A1 | Substituted aryl piperidinylalkynyladenosines as A2AR agonists | ADENOSINE THERAPEUTICS, LLC | 2007-11-22 | — | — | US | disclosed |
| US-20070232559-A1 | 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2007-10-04 | — | — | US | disclosed |
| US-7214665-B2 | 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2007-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170803-A1 | ADJUNCTIVE TREATMENT OF BIOLOGICAL DISEASES | ADORA2A, PDE4A, PDE4B | HSP90B1 711/4885ADORA2A 1/4885ADORA3 7/4885 |
| US-20070232559-A1 | 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF | ADORA2A, ADORA3, ADORA1 | HSP90B1 4386/4885ADORA2A 1/4885ADORA3 2/4885 |
| US-20110091385-A1 | SUBSTITUTED ARYL PIPERIDINYLALKYNYLADENOSINES AS A2AR AGONISTS | ADORA2A, ADORA1, ADORA3 | HSP90B1 4047/4885ADORA2A 1/4885ADORA3 3/4885 |
| US-20090280059-A1 | SUBSTITUTED ARYL PIPERIDINYLALKYNYLADENOSINES AS A2AR AGONISTS | ADORA2A, ADORA1, ADORA3 | HSP90B1 4047/4885ADORA2A 1/4885ADORA3 3/4885 |
| US-20070270373-A1 | Substituted aryl piperidinylalkynyladenosines as A2AR agonists | ADORA2A, ADORA1, ADORA3 | HSP90B1 4047/4885ADORA2A 1/4885ADORA3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.